Sabinsa’s LactoSporin® received the first-place award in 2021 Nutrition Industry Executive (NIE) Awards in the Personal Care / Cosmetics category. The awards, which honor the top new ingredients, are chosen by an expert panel and the NIE editors.
LactoSporin® (Bacillus Ferment Filtrate Extract) is a patented, proprietary, standardized non-living antimicrobial product obtained from the supernatant of the probiotic strain Bacillus coagulans (Weizmannia coagulans) MTCC 5856 (LactoSpore®) developed by Sabinsa. It is a postbiotic ingredient that can modulate skin aging naturally, prevent acne, and positively influence the skin microbiome. Initially evaluated for its excellent antimicrobial activity against skin pathogens, LactoSporin® was also found to inhibit biofilm formation in vitro. It is the first probiotic metabolite to be clinically studied to evaluate its efficacy and safety.
The clinical trial for 21 days showed significant improvement in reducing inflammation, elevation, and redness of acne lesions and reduced sebum secretion. Therefore, this ingredient has the potential to be used in seborrheic conditions. LactoSporin® was safe and showed no irritation in the primary skin irritation patch test, and there were no adverse reactions reported during the clinical trial confirming its safety. LactoSporin® has skin-protecting activities, mediated by a reduction in UV-induced cellular damage and inhibition of matrix-degrading enzymes, as observed by the in vitro studies. Further, LactoSporin® was found safe according to the Organization for Economic Co-operation and Development (OECD) guidelines for its ocular, dermal, and environmental safety.
“Sabinsa is honored to receive this independent affirmation that LactoSporin® has tremendous potential in the marketplace,” said Dr. Muhammed Majeed, Sabinsa founder and chairman.